From 2017, Kappa Santé accompanies IFM (Intergroupe Francophone du Myélome) in the design, implementation and analysis of the EmmY (Epidemiology of Multiple MYeloma) cohort. The study was proposed to all French IFM member centers specialized in the management of multiple myeloma. Among them, a sample of 73 centers willing to participate, was selected to conduct the study.
With the support of the Kappa Santé teams, these centers collect completeness data on their multiple myeloma patients each year and meeting the inclusion criteria of the study, in order to observe the evolution of the therapeutic management of multiple myeloma in France over 7 consecutive years of follow-up.
This national, multicenter, observational study in real-life conditions is based on a repeated annual retrospective collection of data from expert multiple myeloma management centers in order to create a dynamic cohort.
This study, conducted under the aegis of a scientific committee, is being implemented jointly by IFM, Kappa Santé and a consortium of pharmaceutical companies.
A FOLLOW-UP PLANNED OVER SEVEN YEARS
In February 2023, more than 5,250 patients are included and contribute to the richness of the database on more than 500 socio-demographic and clinical variables. The design of the project allows for the exploration of each patient's historical data, and already offers more 6 years of prospective follow-up for the first patients included.
Study progress data as of 07/03/2023
A CHAIN AT THE SNDS
Today, the EMMY cohort represents more than 7,037 person-years for the 3,616 patients in the collection in April 2022, making it one of the largest European multiple myeloma cohorts.